丹麦MediCult
MediCult成立于1987年，总部位于丹麦。根据该公司的网站称，其目前以掌握全球近五分之一的辅助生殖技术培养基市场。Medicult胚胎培养液
2009年提高生育产品业务 默克5510万美元收购MediCult
At MediCult, our motto “Life’s beginning in safe hands” is essential to all employees.

Since its foundation in 1987 MediCult has developed a leading position within the fertility market. Our core competencies lie in the development, manufacturing and marketing of specialized culture media for Assisted Reproduction Technologies (ART).

The ART market is highly attractive supported by the development in several ‘megatrends’ in the surrounding society, incl. the choice of females to give birth to their children later in their life than what was the case historically. In addition, volatility to international economic trends is low. ART plays a key role in renewal of the population in the industrialized world as up to 5 % of all new-born babies are a result of infertility treatment. The desire of couples to have children and the need for society to increase birth rates drive the market – securing double digit growth rates per year.

MediCult has the market’s most comprehensive range of ART media and holds approx. 1/5 of the world market for ART media combined with one of the strongest brands in the industry. We focus on the development of differentiated media products and clinical procedures such as In Vitro Maturation (IVM) media and method.

Our highly qualified employees work closely together with internationally acknowledged researchers to facilitate and innovate ART procedures. We all at MediCult take pride in providing high quality services to our customers. And we are committed to running a high-growth, profitable business to meet the trust and confidence from our more than 3000 shareholders in MediCult.

Thank you for taking an interest in our company.
 MediCult was founded in Norway in 1987 by Doctors Kjell Bertheussen and Nicolai Holst together with Jens U. Holst., after Doctor Bertheussen, professor of biochemistry at Norway's Tromsø University, pioneered the novel Synthetic Serum Replacement (SSRTM)* principle for media production.

Excited by the possibilities, the founders wanted to commercialise the media based on the new SSRTM principle, which is serum-free and thus safer for many applications.

In 1988 MediCult entered the fertility market with media applications for In Vitro Fertilization (IVF) treatments. MediCult has subsequently developed a full range of media products covering all procedures within IVF. Sales have expanded to all parts of the world, and today MediCult is a leading company developing, manufacturing and marketing media to IVF clinics world wide.